We sought to investigate the efficacy and safety of the oral CRTH@ antagonist BI @ ( @ , @ , and @ mg twice daily ) , fluticasone propionate nasal spray ( @ g once daily ) , or oral montelukast ( @ mg once daily ) administered for @ weeks in patients with SAR .